Chronic Obstructive Pulmonary Diseases:Journal of the COPD Foundation

COPD9USA Online CME Faculty Disclosure

Planners and faculty participating in continuing education activities provided by the University of Nebraska Medical Center, Center for Continuing Education are expected to disclose to the audience any significant support or substantial relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. Having an interest in or affiliation with a commercial entity does not preclude making a presentation at a CME activity, but the relationship must be disclosed in advance and any potential conflict of interest must be resolved in accordance with the ACCME Updated Standards for Commercial Support. The planners and faculty have been advised that this activity must be free from commercial bias and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis. Disclosure of these commitments and/or relationships is included in the materials so that participants in the activity may formulate their own judgment in interpreting its content and evaluating its recommendations.

The following faculty have conflicts to disclose:

  • Sandra Adams, MD, MS
    • Grant Recipient: NIH/VA, UT, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis
  • David Au, MD, MS
    • Speaker: Boehringer Ingelheim
  • Russell Bowler MD, PhD
    • Advisor: Boehringer Ingelheim
    • Grant Recipient: MedImmune, Boehringer Ingelheim
  • Richard Casaburi, PhD, MD
    • Consultant: Boehringer Ingelheim, Novartis, Regeneron, GlaxoSmithKline
    • Grant Recipient: Boehringer Ingelheim, Novartis, AstraZeneca
    • Speaker: Boehringer Ingelheim, Novartis, AstraZeneca
  • Bartolome Celli, MD
    • Advisor: GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Almirall
  • Mark Dransfield, MD
    • Grant Recipient: GlaxoSmithKline, Forest
    • Contracted Researcher: Boehringer Ingelheim, GlaxoSmithKline, Pulmonx, PheumRx, Otsuka, Pearl, Forest, AstraZeneca
  • MeiLan Han, MD, MS
    • Consultant: Boehringer Ingelheim, GlaxoSmithKline
  • Edward Ingenito, MD, PhD
    • Employee: Amgen
  • Min Joo, MD
    • Advisor: Grifols
  • Allison A. Lambert, MD
    • Consultant: GLG Consulting and ha
    • Grant Recipient: National Institutes of Health
  • Trina Limberg, BS, RRT, FAACVPR, FAARC
    • Consultant: Nonin
  • Barry Make, MD
    • Advisor: Boehringer Ingelheim, AstraZeneca, CSL Bering, Forest
    • DSMB: Spiration
  • Fernando Martinez, MD, MS
    • Consultant: Amgen, Carden Jennings, CSA Medical, Forest, Ikaria, Janssen, Merck, Nycomed/Takeda, GlaxoSmithKline, Pearl, Roche, Axon, Veracyte
    • Committee Member: Forest, Janssen, Nycomed/Takeda, GlaxoSmithKline, Gilead Sciences, Promedior, Bayer, Johnson & Johnson
    • FDA Mock Panel: Boehringer Ingelheim, GlaxoSmithKline
    • DSMB: Stromedix, GlaxoSmithKline
    • Speaker: Nycomed/Takeda
    • CME Programs: Annenberg, CME Incite, MedScape, Miller, Paradigm, Peer Voice, NACE
    • Investigational/Off-Label Use of Drugs Disclosure: Azithromycin in AECOPD prevention
  • Caroline Owen, MD, PhD, FRCP
    • Shareholder: Pfizer, Bristol-Myer Squibb, Merck and Co
  • Stephen Rennard, MD
    • Consultant: GlaxoSmithKline, Boehringer Ingelheim, Forest, AstraZeneca, Chiesi, CME Incite, Takeda, Regeneron, Pearl, CIPLA, ABIM, Merck, Medimmune, Synapse, Nycomed, Dailchi Sankyo, Novartis, Johnson and Johnson, Quadrant, GersonLehman, Able Associates, CSL Behring, CTS Carmel, Decision Res, FirstWord, Gilead, Guidepoint Global, Pulmatrix, Saatchi and Saatchi, Schlesinger Assoc, Cory Paeth, Frankel Group, Medical Knowledge, Pro Ed Comm, LEK Consulting
    • Grant Recipient: GlaxoSmithKline
    • Speaker: Forest
  • Frank Sciurba, MD
    • Grant Recipient: PneumRX, Pulmonx
  • Robert Stockley, MD, FRCP, DSc, FERS
    • Advisor: GlaxoSmithKline, CSL Behring, Chiesi, Boehringer Ingelheim, Grifols
    • Speaker: GlaxoSmithKline, CSL Behring, Chiesi
    • Grant Recipient: CSL Behring, Grifols
  • Gerard Turino, MD
    • Consultant: Baxter
    • Grant Recipient: CSL Behring, Boehringer Ingelheim
  • David Vines, RRT
    • Advisor: Boehringer Ingelheim, Bayer
    • Speaker: Teleflex Medical
    • Grant Recipient: Kimberly Clark, Aerogen
  • George Washko, MD
    • Spouse Employer: Merck
    • Consultant: GlaxoSmithKline
  • Prescott Woodruff, MD, MPH
    • Advisor: Janssen, Neostem, Genentech
    • Grant Recipient: Genentech
    • Consultant: Roche, Novartis, AstraZeneca
  • Barbara Yawn, MD, MSc, MSPH
    • Advisor: Boehringer Ingelheim
    • Grant Recipient: Boehringer Ingelheim

The following member of the planning committee has conflicts to disclose:

  • Anita Pye, PhD
    • Microbiology Reviewer/Advisor: Aradigm Corporation